As we head into ASCO weekend, cancer experts will highlight closely watched data sets to be unveiled at the meeting. This discussion will take a close look at oncology's hottest fields, including CAR-T and precision medicine, as panelists zero in on the conference's most highly anticipated studies, 2021's biggest research trends, and the data they're most looking forward to seeing.

Featured Speakers

Jennifer Keating Litton, M.D.

Vice President of Clinical Research and Professor
The University of Texas MD Anderson Cancer Center

Jennifer Keating Litton, M.D., is Vice President of Clinical Research and Professor in the Department of Breast Medical Oncology and Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center.  She holds an additional faculty position in the Graduate School of Biomedical Sciences at The University of Texas Health Sciences Center in Houston.  She attended Duke University, with degrees in English and in History and The University of Massachusetts Medical School.  After completing an Internal Medicine Residency at Baylor College of Medicine, she then served as Chief Medical Resident.  She completed a fellowship in Medical Oncology at The University of Texas MD Anderson Cancer Center before joining the faculty in the Department of Breast Medical Oncology.  Her research interests include the treatment of young breast cancer patients, including the treatment of breast cancer during pregnancy, treatment-related infertility, hereditary cancer syndromes, immunotherapy and triple negative breast cancer.  She is the principle investigator for multiple clinical trials.  She serves as a member of the National Cancer Center Network National Guidelines Panel for Hereditary Breast and Ovarian Cancer Syndromes and has been appointed to the Breast Immuno-Oncology Task Force of the National Cancer Institute Breast Cancer Steering Committee and Co-Chair of the Society for Immunotherapy of Cancer (SITC) Breast Cancer Subcommittee.  She has authored multiple abstracts, peer-reviewed journal articles, and book chapters.  Dr. Litton has served on the boards of the St. Luke’s Episcopal Health Charities, the Children’s Fund, Suites of Hope and is an alumni of the Texas Lyceum.  She lives in Houston with her husband Todd and their three children.

Jill O'Donnell-Tormey, Ph.D.

Chief Executive Officer and Director of Scientific Affairs
Cancer Research Institute (CRI)

Jill O’Donnell-Tormey, Ph.D., is chief executive officer and director of scientific affairs of the Cancer Research Institute (CRI), a nonprofit organization founded in 1953 that is today the global leader in supporting and coordinating research aimed at harnessing the immune system’s power to conquer all cancers. She joined the organization in 1987, and has been chief executive since 1993. Prior to joining CRI, she served as a research associate in the department of medicine at Cornell University Medical College and as a postdoctoral fellow in the laboratory of cellular physiology and immunology at The Rockefeller University.

In 2020, Dr. O'Donnell-Tormey was awarded the 2020 Public Service Award from the Society for Immunotherapy of Cancer (SITC) for her work as a true leader and strong advocate for cancer immunotherapy through her continuous service at the Cancer Research Institute (CRI).

Joseph Alvarnas, M.D.

Vice President of Government Affairs and Chief Clinical Advisor

Joseph Alvarnas, M.D.,is a hematologist and an expert in bone marrow and stem cell transplantation at City of Hope in Duarte, California, where he serves also as vice president of Government Affairs and Chief Clinical Advisor for AccessHope. He is also a clinical professor in the Department of Hematology and Hematopoietic Cell Transplantation.

In his role, Dr. Alvarnas is accountable for leading advocacy efforts at the Federal, State, and local levels related to the City of Hope. He also works under the President of Strategy and Business Ventures to assist in developing, marketing, and operationalizing the clinical infrastructure and activities related to the employer and payer strategies.

Mike Riley

Regional Biologics President for North America

Mike Riley is the Regional Biologics President for North America and has overall responsibility for strategy and management of the biologics business in North America. Previously, he served as Vice President/General Manager of Catalent Biologics for five years. Mike has 15 years of experience at Catalent where he has a demonstrated track record of strategic growth leadership across multiple businesses, previously serving as Vice President of Strategy, Advanced Delivery Technologies and Vice President, Global Business Development for Catalent Sterile Technologies. Prior to joining Catalent, Mike worked as a management consultant for Marakon Associates, providing strategic advisory to companies across multiple industries. Mike holds a B.A. from Duke University, and a MBA from The Wharton School, University of Pennsylvania.

Alexey Aleshin, MD, MBA

Vice President, Oncology

Dr. Alexey Aleshin has led the oncology clinical development efforts at Natera, Inc. since 2018. Prior to this, he worked on the various novel ctDNA technologies while at Stanford University. He remains a clinical adjunct faculty in the division of Hematology at Stanford, where his work focuses on novel diagnostics assays for treatment decision support in hematologic malignancies. He received a B.A. in Statistics from UC Berkeley and his M.D./M.B.A. degrees at UCLA. He completed his clinical training in internal medicine and hematology/oncology at Stanford University.

Sponsored by: 



Register now for this roundtable